Core Insights - RE/MAX reported revenue of $74.47 million for the quarter ended March 2025, reflecting a year-over-year decline of 4.9% [1] - The company's EPS for the same period was $0.24, an increase from $0.20 a year ago, resulting in an EPS surprise of +33.33% compared to the consensus estimate of $0.18 [1] Revenue Breakdown - Marketing Funds fees amounted to $18.86 million, exceeding the two-analyst average estimate of $18.10 million, but showing a year-over-year decline of 6.6% [4] - Continuing franchise fees were reported at $29.35 million, slightly above the estimated $29.32 million, with a year-over-year decrease of 5.6% [4] - Franchise sales and other revenue totaled $7.03 million, below the average estimate of $7.99 million, marking a year-over-year decline of 12.7% [4] - Broker fees reached $11.43 million, surpassing the estimated $11.12 million, and showing a year-over-year increase of 6.7% [4] - Annual dues were reported at $7.79 million, slightly below the average estimate of $8.02 million, with a year-over-year decline of 5.3% [4] Stock Performance - Over the past month, RE/MAX shares have returned -8.7%, compared to a -0.7% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Core Insights - Ingersoll Rand reported $1.72 billion in revenue for Q1 2025, a year-over-year increase of 2.8%, but fell short of the Zacks Consensus Estimate by 1.00% [1] - The company's EPS for the quarter was $0.72, down from $0.78 a year ago, representing an EPS surprise of -1.37% compared to the consensus estimate of $0.73 [1] Revenue Performance - Precision and Science Technologies revenue was $364.70 million, exceeding the estimated $364.25 million, reflecting a year-over-year increase of 22.9% [4] - Industrial Technologies and Services revenue was reported at $1.35 billion, slightly below the $1.37 billion estimate, showing a year-over-year decline of 1.6% [4] EBITDA Analysis - Adjusted EBITDA for Precision & Science Technologies was $106.20 million, surpassing the average estimate of $103.89 million [4] - Adjusted EBITDA for Industrial Technologies & Services was $389.10 million, which was below the estimated $406.83 million [4] Stock Performance - Ingersoll Rand's shares have returned -7.7% over the past month, compared to a -0.7% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Core Insights - CVS Health reported revenue of $94.59 billion for the quarter ended March 2025, marking a year-over-year increase of 7% and exceeding the Zacks Consensus Estimate of $92.95 billion by 1.76% [1] - The company achieved an EPS of $2.25, up from $1.31 a year ago, resulting in an EPS surprise of 31.58% compared to the consensus estimate of $1.71 [1] Financial Metrics - Medical benefit ratio (MBR) was reported at 87.3%, lower than the average estimate of 88.6% [4] - Total medical membership reached 27.08 million, surpassing the average estimate of 25.99 million [4] - Revenue from Health Care Benefits was $34.81 billion, exceeding the average estimate of $33.66 billion, reflecting an 8% year-over-year increase [4] - Revenue from the Pharmacy & Consumer Wellness Segment was $31.91 billion, above the average estimate of $31.20 billion, with an 11.1% year-over-year increase [4] - Net revenue from the Health Services segment was $40.12 billion, below the average estimate of $43.36 billion, showing a slight decline of 0.4% year-over-year [4] - Pharmacy claims processed totaled 464.2 million, slightly below the average estimate of 467.42 million [4] - Revenue from the Pharmacy segment was $26.08 billion, exceeding the average estimate of $25.29 billion, with a year-over-year increase of 14.5% [4] - Revenue from the front store of the Pharmacy & Consumer Wellness Segment was $5.24 billion, below the average estimate of $5.43 billion, reflecting a decline of 2.4% year-over-year [4] - Net investment income in the Health Care Benefits Segment was $387 million, surpassing the average estimate of $297.44 million, representing a 9.6% year-over-year increase [4] - Revenue from services in the Health Care Benefits Segment was $1.62 billion, slightly above the average estimate of $1.60 billion, with a year-over-year increase of 7.4% [4] Stock Performance - CVS Health shares have returned -2% over the past month, compared to a -0.7% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Insights - Parsons (PSN) reported revenue of $1.55 billion for the quarter ended March 2025, reflecting a 1.2% increase year-over-year, but a -3.45% miss against the Zacks Consensus Estimate of $1.61 billion [1] - The company's EPS was $0.78, up from $0.70 in the same quarter last year, resulting in a +5.41% surprise compared to the consensus estimate of $0.74 [1] Revenue Performance - Critical Infrastructure revenue was $711.80 million, exceeding the estimated $704.86 million, marking a +13.7% change from the previous year [4] - Federal Solutions revenue was $842.56 million, below the estimated $894.52 million, representing a -7.4% change year-over-year [4] EBITDA Analysis - Adjusted EBITDA for Critical Infrastructure was $73.19 million, surpassing the average estimate of $59.15 million from two analysts [4] - Adjusted EBITDA for Federal Solutions was $75.58 million, slightly below the estimated $79.70 million from two analysts [4] Stock Performance - Shares of Parsons have returned +15.3% over the past month, contrasting with a -0.2% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Core Insights - Flowserve reported revenue of $1.14 billion for the quarter ended March 2025, reflecting a 5.3% increase year-over-year and surpassing the Zacks Consensus Estimate of $1.11 billion by 3.35% [1] - The company's EPS was $0.72, up from $0.58 in the same quarter last year, resulting in an EPS surprise of 22.03% compared to the consensus estimate of $0.59 [1] Revenue Performance - Sales from FPD segment reached $783.10 million, exceeding the average estimate of $749.56 million, with a year-over-year change of 1.9% [4] - FCD segment sales were reported at $364.10 million, above the average estimate of $358.78 million, showing a significant year-over-year increase of 14.2% [4] - Intersegment sales reported a slight decline of -$2.70 million, compared to the average estimate of -$2.20 million, but still represented a year-over-year change of 10.8% [4] Operating Income - Adjusted Operating Income for the FPD segment was $138.60 million, surpassing the average estimate of $116.22 million [4] - Adjusted Operating Income for the FCD segment was $44.60 million, slightly above the average estimate of $42.93 million [4] Stock Performance - Flowserve's shares have returned -8.6% over the past month, contrasting with the Zacks S&P 500 composite's -0.8% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Core Insights - Corning reported revenue of $3.68 billion for the quarter ended March 2025, reflecting a year-over-year increase of 12.9% and surpassing the Zacks Consensus Estimate by 3.87% [1] - The company's EPS for the quarter was $0.54, an increase from $0.38 in the same quarter last year, exceeding the consensus estimate of $0.50 by 8.00% [1] Financial Performance - Net Sales in Display Technologies reached $905 million, slightly below the average estimate of $912.96 million, with a year-over-year change of +3.8% [4] - Net Sales in Optical Communications were $1.36 billion, exceeding the estimated $1.27 billion, marking a significant year-over-year increase of +45.7% [4] - Net Sales in Hemlock and Emerging Growth Businesses totaled $244 million, falling short of the average estimate of $321.84 million, representing a year-over-year decline of -21.5% [4] - Net Sales in Life Sciences were $234 million, below the average estimate of $249.16 million, with a slight year-over-year decrease of -0.9% [4] - Net Sales in Specialty Materials reached $501 million, surpassing the average estimate of $468.60 million, reflecting a year-over-year increase of +10.4% [4] Segment Performance - Segment Net Income for Optical Communications was $201 million, exceeding the average estimate of $169.93 million [4] - Segment Net Income for Display Technologies was $243 million, above the average estimate of $221.66 million [4] - Segment Net Income for Life Sciences was $13 million, below the average estimate of $19.50 million [4] - Segment Net Income for Specialty Materials was $74 million, slightly above the average estimate of $72.16 million [4] - Segment Net Income for Hemlock and Emerging Growth Businesses reported a loss of -$16 million, worse than the average estimate of -$7.78 million [4] Stock Performance - Corning's shares have returned -3.7% over the past month, compared to a -0.8% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Insights - Honeywell International Inc. reported revenue of $9.82 billion for the quarter ended March 2025, reflecting a year-over-year increase of 7.9% and surpassing the Zacks Consensus Estimate by 2.59% [1] - The company's EPS for the quarter was $2.51, up from $2.25 in the same quarter last year, resulting in an EPS surprise of 13.57% compared to the consensus estimate of $2.21 [1] Financial Performance - Net Sales in Building Automation reached $1.69 billion, exceeding the estimated $1.59 billion, marking an 18.7% increase year-over-year [4] - Aerospace Technologies generated $4.17 billion in Net Sales, surpassing the $4.04 billion estimate, with a year-over-year growth of 13.7% [4] - Corporate and All Other segment reported Net Sales of $19 million, significantly higher than the estimated $10.85 million, representing a 171.4% increase compared to the previous year [4] Segment Profit Analysis - Aerospace Technologies segment profit was $1.10 billion, slightly above the average estimate of $1.06 billion [4] - Building Automation segment profit reached $440 million, exceeding the average estimate of $411.37 million [4] - Energy and Sustainability Solutions segment profit was $346 million, close to the estimated $348.48 million [4] - Industrial Automation segment profit was $424 million, slightly below the average estimate of $430.38 million [4] - Corporate and All Other segment reported a loss of $51 million, better than the average estimate of a loss of $74.95 million [4] Stock Performance - Honeywell's shares have returned -5.2% over the past month, compared to a -0.8% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Insights - Legget & Platt reported revenue of $1.02 billion for the quarter ended March 2025, reflecting a 6.8% decline year-over-year and a slight miss of 0.53% against the Zacks Consensus Estimate of $1.03 billion [1] - The company's EPS was $0.24, which is an increase from $0.23 in the same quarter last year, resulting in a positive surprise of 4.35% compared to the consensus estimate of $0.23 [1] Revenue and Earnings Performance - The change in organic sales for Bedding Products was -12%, significantly worse than the estimated -4% [4] - Specialized Products saw a -5% change in organic sales, compared to an average estimate of -3.1% [4] - Furniture, Flooring, and Textile Products experienced a -1% change in organic sales, better than the estimated -5.4% [4] - Overall change in organic sales was -7%, against an estimate of -5.6% [4] Trade Sales and EBIT Analysis - Trade sales for Furniture, Flooring, and Textile Products were reported at $331.30 million, exceeding the average estimate of $322.63 million, with a year-over-year change of -0.5% [4] - Trade sales for Specialized Products were $300.10 million, slightly above the average estimate of $298.78 million, reflecting a -5% year-over-year change [4] - Trade sales for Bedding Products were $390.70 million, below the average estimate of $409.90 million, indicating a -12.8% year-over-year decline [4] - EBIT for Bedding Products was $9.60 million, significantly lower than the average estimate of $18.65 million [4] - EBIT for Specialized Products was $28.40 million, surpassing the average estimate of $20.42 million [4] - Adjusted EBIT for Specialized Products was $31.80 million, exceeding the average estimate of $23 million [4] - Adjusted EBIT for Bedding Products was $13 million, below the average estimate of $16.45 million [4] - Adjusted EBIT for Furniture, Flooring, and Textile Products was $21.70 million, above the average estimate of $18.90 million [4] Stock Performance - Legget & Platt's shares have returned -8.7% over the past month, compared to a -4.3% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

The upcoming report from Phillips 66 (PSX) is expected to reveal quarterly loss of $0.60 per share, indicating a decline of 131.6% compared to the year-ago period. Analysts forecast revenues of $30.65 billion, representing a decrease of 15.9% year over year. The consensus EPS estimate for the quarter has undergone an upward revision of 1% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe ...